Europe Botulinum Toxin Market Size, Share & Industry Trends Analysis Report By Product, By Application (Therapeutic and Aesthetic), By End User (Hospitals, Dermatology Clinics and Spas & Cosmetic Centers, By Country and Growth Forecast, 2022 - 2028

The Europe Botulinum Toxin Market is expected to witness market growth of 10.6% CAGR during the forecast period (2022-2028).

In order to inhibit the fusion of cholinergic vesicles with the cell membrane, the light (L) chain interacts with several proteins in the nerve terminals, including syntaxin, synaptosomal associated protein, or SNAP, and vesicle-associated membrane protein. After the injection, the paralytic effect peaks four to seven days later. Units of biological activity are the units used to express the dosage of all commercially produced botulinum toxins.

The computed median intraperitoneal lethal dose (LD50) for female Swiss-Webster mice is equal to one unit of botulinum toxin. The blocked neurotransmitter release is irreversible, yet the afflicted nerve terminals do not deteriorate. Nerve terminal sprouting and the development of new synaptic connections, which typically take two to three months, can restore function.

By preventing alpha motor neuron transmission at the neuromuscular junction, botulinum toxin causes striated muscle weakening. Its usage in disorders with excessive muscle activity, such as dystonia, is a result of this. Inhibiting transmission at gamma neurons within muscle spindles may change the overactivity of reflexes.

Acetylcholine is released at the presynaptic membrane of cholinergic neurons but is not released when the Clostridium botulinum toxin type A neurotoxin complex is present. In order to treat neuromuscular diseases, Botox was originally approved in the European Union by intramuscular injection. Botox for the treatment of axillary hyperhidrosis was proposed as a new indication through the Mutual Recognition Procedure (MRP) by the Marketing Authorization Holder, Allergan Pharmaceuticals (Ireland) Ltd.

The Germany market dominated the Europe Botulinum Toxin Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $708.9 Million by 2028.The UK market is anticipated to grow at a CAGR of 9.6% during (2022 - 2028). Additionally, The France market is expected to exhibit a CAGR of 11.4% during (2022 - 2028).

Based on Product, the market is segmented into Type A and Type B. Based on Application, the market is segmented into Therapeutic and Aesthetic. Based on End User, the market is segmented into Hospitals, Dermatology Clinics and Spas & Cosmetic Centers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Evolus, Inc. (Alphaeon Corporation), Merz Pharma GmbH & Co. KGaA, AbbVie, Inc., Ipsen Pharma, Galderma S.A., USWM, LLC, and Metabiologics, Inc. (Object Pharma).

Scope of the Study

Market Segments Covered in the Report:

By Product

• Type A
• Type B

By Application

• Therapeutic
• Aesthetic

By End User

• Hospitals
• Dermatology Clinics
• Spas & Cosmetic Centers

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Evolus, Inc. (Alphaeon Corporation)
• Merz Pharma GmbH & Co. KGaA
• AbbVie, Inc.
• Ipsen Pharma
• Galderma S.A.
• USWM, LLC
• Metabiologics, Inc. (Object Pharma)

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free